A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

September 11, 2018

Study Completion Date

January 9, 2019

Conditions

Refractory Diffuse Large B-Cell Lymphoma

Interventions

BIOLOGICAL

C-CAR-011

lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene.

Trial Locations (1)

Hematological Department, People's Hospital of Jiangsu Province, Nanjing

All Listed Sponsors

collaborator

The First Affiliated Hospital with Nanjing Medical University

OTHER

lead

Shanghai AbelZeta Ltd.

INDUSTRY

NCT02976857 - A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL Subjects | Biotech Hunter | Biotech Hunter